We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




RFA Benefits Some Lung Cancer Patients

By HospiMedica staff writers
Posted on 20 Dec 2001
Preliminary results of a study suggest that radiofrequency ablation (RFA) guided by computed tomography (CT) may be an effective way of treating patients with non-small-cell lung cancer (NSCLC) whose tumors are unresectable. More...
The study was reported in a scientific paper presented by Patrick E. Sewell, Jr., M.D., of the University of Mississippi Medical Center (Jackson, USA), at the annual meeting of the Radiological Society of North America (RSNA) in Chicago (IL, USA).

The study involved 29 patients with nonresectable NSCLC, most with squamous carcinoma or adenocarcinoma. More than half (56%) had stage IA or IB disease and another 20% had stage IIIB cancer. General anesthesia was given to 86% of patients, but 14% had the procedure while sedated but conscious. Doctors placed a LeVeen needle electrode in the tumor under CT guidance. Radiofrequency energy was then applied to an end-point of full system impedance, based on an algorithm that classified the tumors as parenchymal (59%), pleural-based (26%), or hilar/mediastinal (15%). After treatment, patients had regular follow-up CT chest studies.

Except for two lesions that had to be retreated, all thermal lesions progressively decreased in size, showing that only nonviable tissue remained. At three months, 23 of the 29 patients were alive with no evidence of recurrence. Nine deaths occurred after the procedure but none was caused by progression of the cancer in the lungs. After an average follow-up of 13 months, 20 of the 29 patients were alive, 19 of them without any evidence of viable cancer at the treatment site. The only major complication was parenchymal bleeding in one patient with marked coronary and cerebral atherosclerotic disease. Nearly one-third of the patients developed pneumothorax but it was promptly evacuated and only 15% required a chest tube. Pleural effusion complicated 15% of procedures and was linked to lesion size and treatment time.

Dr. Sewell concluded that RFA is a safe procedure with minor morbidity and mortality and provides reliable and reproducible necrosis of NSCLC. "For stage IA and IB tumors, preliminary results suggest that it may be an excellent substitute for patients unable to undergo traditional surgical resection.”




Related Links:
Univ. of Mississippi

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Syringes
Prefilled Saline Flush Syringes
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.